Steven Gore, MD

Professor of Internal Medicine (Hematology); Director of Hematologic Malignancies

Research Departments & Organizations

Internal Medicine: Hematology

Yale Cancer Center: Developmental Therapeutics

Research Interests

DNA Methylation; Hematology; Histone Deacetylases; Leukemia; Myelodysplastic Syndromes

Research Summary

Specialized Terms: Clinical trials for patients with leukemia and meylodysplastic syndromes with a focus on translational research. Mechanism behind the clinical activity of drugs which putatively target epigenetic dysregulation.

Clinical Trials

Conditions Study Title
Other Hematopoietic, Sickle Cell Disorders Dronabinol for Pain and Inflammation in Adults Living with Sickle Cell Disease
Leukemia, other Phase 1b Dose Escalation followed by Phase 2 treatment. Participants will be evaluable for inclusion in the Phase 1b and Phase 2 portions of the study if they receive at least one dose of protocol therapy.
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions.
Leukemia, other Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia
Lymphoid Leukemia A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Leukemia, other A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML
Leukemia, not otherwise specified, Leukemia, other Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Leukemia, not otherwise specified, Leukemia, other PTQA: A New Paradigm of Transfusion Decision Support for Patients With MDS
Leukemia, other, Myeloid and Monocytic Leukemia A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes
Myeloid and Monocytic Leukemia Phase I, International, Multicentre, Open-label, Non-randomised, Non-comparative Study of Intravenously Administered S64315, a Mcl-1 Inhibitor, in Patients With Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS)
Leukemia, other An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Patients With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Myeloid and Monocytic Leukemia A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)
Myeloid and Monocytic Leukemia The National Myelodysplastic Syndromes Natural History Study
Myeloid and Monocytic Leukemia A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination With 5-Azacytidine (5AC, NSC 102816) in Elderly Patients With Acute Myeloid Leukemia (AML)
Myeloid and Monocytic Leukemia A Phase 1, Open-label, Dose Finding Study of CC-90009 in Subjects With Relapsed, Refractory Acute Myeloid Leukemia
Leukemia, other Assessment of Quality of Life, Prognostic Understanding, and Perceived Goals of Care in Patients with Leukemia
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Leukemia, other A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Myeloid and Monocytic Leukemia A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Edit this profile

Contact Info

Steven Gore, MD
Mailing Address
Hematology25 York Street
PO Box 208028

New Haven, CT 06520-8028

Curriculum Vitae